CVSA vs FRPT
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
CVSA presents a dichotomy between strong operational performance and deteriorating technicals. While the Piotroski F-Score of 4/9 indicates stable but non-optimal financial health, the company boasts an exceptional earnings track record with consistent beats over 25 quarters. Valuation is attractive on a PEG basis (0.82), though the current price of $107.63 trades at a premium to both the Graham Number ($77.96) and Intrinsic Value ($95.4). The primary concerns are a bearish technical trend (-29.6% over 6 months) and weak liquidity ratios.
Freshpet exhibits a stable financial foundation with a Piotroski F-Score of 4/9 and an exceptionally strong liquidity profile (Current Ratio 5.54). While the stock trades at a significant premium to its Graham Number ($38.72), it remains below its growth-based intrinsic value of $79.65. Explosive earnings growth (79.2% YoY) is the primary bullish driver, yet this is offset by a high PEG ratio of 3.77 and a bearish technical trend. The company is transitioning from a loss-making entity to a profitable one, but valuation remains stretched relative to revenue growth.
Compare Another Pair
Related Comparisons
CVSA vs FRPT: Head-to-Head Comparison
This page compares Covista Inc. (CVSA) and Freshpet, Inc. (FRPT) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.